3:18 PM
 | 
Oct 10, 2017
 |  BC Extra  |  Company News

AbbVie, Turnstone in oncolytic virus deal

AbbVie Inc. (NYSE:ABBV) acquired options to license exclusive, worldwide rights to three oncolytic viral immunotherapies from Turnstone Biologics Inc. (Ottawa, Ontario), including the...

Read the full 105 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >